Molecular Pathology of Lung Cancer

Bozkurtlar, Emine; Kaya, Handan

doi:10.4274/nts.2018.004

Cited by 1 publication

(10 citation statements)

References 57 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Characterized by complex genomic alterations, lung cancer often presents as a solid tumor, which can be successfully treated using targeted therapies. 3 , 5 Differences can be observed in lung cancer patients with similar clinical and histopathological features in prognosis and response to treatment. Therefore, molecular tests have become more important for administering the most appropriate treatment for each patient.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, molecular tests have become more important for administering the most appropriate treatment for each patient. 3 , 19 At present, tumor samples are used for diagnostic and molecular tests. 2 According to the recently updated National Comprehensive Cancer Network guidelines for NSCLC, molecular testing is recommended as a routine for 9 genes: ALK, ROS1, EGFR, KRAS/NRAS, BRAF, RET, MET, ERBB2, and PDL‐1 .…”

Section: Discussionmentioning

confidence: 99%

“… 24 , 25 Genetic mutations often occur in EGFR, KRAS, TP53, CDKN2A, and NF1 in patients with lung ADC. 3 ,5,12,23, 26 PIK3CA, TP53, NF1, CDKN2A, and SOX2 mutations are also frequently detected in SCC patients. 5 ,12, 27 In this study, the most common VSS were compatible with the underlying histopathology.…”

Section: Discussionmentioning

confidence: 99%

“…Lung cancer, the most common type of malignancy in all societies, generally has a poor prognosis, and is the leading cause of cancer-associated mortality. 1 - 3 Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer. It is generally diagnosed in advanced stages due to its silent clinical symptoms.…”

Section: Introductionmentioning

confidence: 99%

“… 8 , 9 For lung cancer, recent studies showing the distribution of the molecular profile have demonstrated their molecular heterogeneity. 2 , 3 Characterization of NSCLC-specific genomic alterations is crucial to creating new, more successful treatment protocols specific to the patient and tumor type.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Evaluation of the Mutation Profile via Next-Generation Sequencing in a Turkish Population With Non-small Cell Lung Cancer

et al. 2021

View full text Add to dashboard Cite

Background Lung cancer is the most common cancer type worldwide, with non-small cell lung cancer being the most frequently studied. Identifying of cancer-related genes in non-small cell lung cancer is crucial for developing individualized treatment, particularly as mutation profiles can vary by country and ethnicity. Aims To identify comprehensive mutation profiles in a cohort of Turkish patients with non-small cell lung cancer using the next-generation sequencing. Study Design Retrospective cross-sectional study. Methods In total, 72 cancer-related genes and 4149 variants were recorded in the non-small cell lung cancer panel, and their relationship with clinical and histopathological features was investigated through next-generation sequencing. Results Among 507 patients, 420 (82.8%) were males and 87 (17.2%) were females. Percentages of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (11%), B-Raf proto-oncogene, serine/threonine kinase (8%), and neurofibromatosis type 1 (6%) mutations were higher than those reported in the literature. Males had a higher rate of Kirsten rat sarcoma 2 viral oncogene homolog mutations ( P = .102), whereas epidermal growth factor receptor mutations were statistically more common in females ( P = .001). Multiple variants of strong significance were identified in 6.3% patients diagnosed with adenocarcinoma, most of whom were smokers. Kirsten rat sarcoma 2 viral oncogene homolog and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha mutations were most commonly observed. Conclusion This study shows that Turkish patients have higher rates of PIK3CA, BRAF and NF1 mutations compared to the literature. Studies to determine the molecular profile specific to Turkish people will guide clinicians in treatment and contribute significantly to determining priorities in diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%